"L'Hôpital Privé Sévigné est un établissement de santé pluridisciplinaire situé à Cesson-Sévigné, en Bretagne. Il fait partie du Groupe Vivalto Santé, troisième acteur national de l'hospitalisation privée."

During the past decade, Hôpital Privé Sévigné conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Privé Sévigné" #1 sponsor was "French Innovative Leukemia Organisation" with 3 trials, followed by "Intergroupe Francophone du Myelome" with 3 trials sponsored, "Rennes University Hospital" with 3 trials sponsored, "Groupe Francophone des Myelodysplasies" with 2 trials sponsored and "Hôpital Privé Sévigné" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Privé Sévigné" #1 collaborator was "Janssen-Cilag Ltd." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Baxter Healthcare Corporation" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Privé Sévigné" are "Analgesia" (2 trials), "Bradycardia" (2 trials), "Multiple Myeloma" (2 trials), "Acute Kidney Injury (AKI)" (1 trials) and "Anesthesia" (1 trials). Many other conditions were trialed in "Hôpital Privé Sévigné" in a lesser frequency.

Most popular intervention types in "Hôpital Privé Sévigné" are "Drug" (12 trials), "Other" (5 trials), "Device" (3 trials), "Procedure" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "ACA Continuation" (1 trials), "ASCT" (1 trials), "Antithrombotic" (1 trials), "Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)" (1 trials) and "Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Privé Sévigné" are 21 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hôpital Privé Sévigné". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Hôpital Privé Sévigné, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Privé Sévigné, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".